The Vanguard Group, Inc. recently announced the acquisition of new stake in Sarepta Therapeutics Inc. (NASDAQ:SRPT). The institutional investor has increased its shareholding in the Healthcare company by 1.40% to 6.4 million shares with purchase of 88119.0 shares. This fresh investment now brings its stake to 8.21% valued currently at $975.17 million. In addition, Capital Research & Management Co…. raised its holdings by 1.47 million to 3.87 million shares. And BlackRock Fund Advisors has lifted its position by 1.20% or 43898.0 shares – to 3.71 million shares.
With over 0.63 million Sarepta Therapeutics Inc. (SRPT) shares trading Monday and a closing price of $163.49 on the day, the dollar volume was approximately $103.77 million. The shares have shown a positive weekly performance of 0.53% and its price on 07/06/20 gained nearly 0.45%. Currently, there are 76.43M common shares owned by the public and among those 74.06M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 23 analysts who have offered their price forecasts for SRPT have a consensus price objective of $196.19. The analysts have set the share’s price value over the next 12 months at a high of $260.00 and a low of $152.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Sarepta Therapeutics Inc. stock is 1.70 for the next 12 months. The average price target is 15.62% above its last price level and an upside to the estimated low will see the stock lose -7.56% over that period. But an upside of 37.12% will see the stock hit the forecast high price target while mean target price for the stock is $192.00.
Insiders at the company have transacted a total of 74 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 53 of these insider trades were purchases, accounting for 581,010 shares. Insider sales of the common stock occurred on 21 occasions, with total insider shares sold totaling 555,111 shares.
The top 3 mutual fund holders in Sarepta Therapeutics Inc. are American Funds Growth Fund of Ame, Vanguard Total Stock Market Index, and Vanguard Small Cap Index Fund. American Funds Growth Fund of Ame owns 2.63 million shares of the company’s stock, all valued at over $399.8 million. The company bought an additional 0.94 million shares recently to bring their total holdings to about 3.37% of the shares outstanding. Vanguard Total Stock Market Index sold 6740.0 shares to see its total holdings shrink to 2.05 million shares valued at over $311.72 million and representing 2.63% of the shares outstanding. Vanguard Small Cap Index Fund sold 15219.0 shares to bring its total holdings to over 1.83 million shares at a value of $279.27 million. Vanguard Small Cap Index Fund now owns shares totaling to 2.35% of the shares outstanding.
Shares of Sarepta Therapeutics Inc. (NASDAQ: SRPT) opened at $163.25, up $0.5 from a prior closing price of $162.75. However, the script later closed the day at $163.49, up 0.45%. The company’s stock has a 5-day price change of 0.53% and 74.63% over the past three months. SRPT shares are trading 26.70% year to date (YTD), with the 12-month market performance up to 8.42% higher. It has a 12-month low price of $72.05 and touched a high of $172.70 over the same period. Currently, 0.63 million shares have been traded, compared to an average intraday trading volume of 956.85K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.02%, 12.12%, and 41.20% respectively.
Institutional ownership of Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares accounts for 95.00% of the company’s 76.43M shares outstanding. Mutual fund holders own 5.46%, while other institutional holders and individual stakeholders account for 59.34% and 36.69% respectively.
It has a market capitalization of $12.98B and a beta (3y monthly) value of 1.92. The stock’s earnings-per-share (ttm) stands at -$8.83. The company has a Quick Ratio of 7.70 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.26% over the week and 3.88% over the month.
Analysts forecast that Sarepta Therapeutics Inc. (SRPT) will achieve an EPS of -$1.7 for the current quarter, -$1.56 for the next quarter and -$2.34 for 2021. The lowest estimate earnings-per-share for the quarter is -$3.24 while analysts give the company a high EPS estimate of -$1.06. Comparatively, EPS for the current quarter was -$3.74 a year ago. Earnings per share for the fiscal year are expected to decrease by -77.80%, and 54.80% over the next financial year. EPS should grow at an annualized rate of -0.20% over the next five years, compared to -23.40% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 23 brokerage firm advisors rate Sarepta Therapeutics Inc. (SRPT) as a “Strong Buy” at a consensus score of 1.70. Specifically, 20 Wall Street analysts polled rate the stock as a buy, while 1 of the 23 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the SRPT, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on March 31, 2020, with the firm’s price target at $183. Guggenheim coverage for the Sarepta Therapeutics Inc. (SRPT) stock in a research note released on November 01, 2019 offered a Buy rating with a price target of $183. Needham was of a view on August 21, 2019 that the stock is Buy, while Morgan Stanley gave the stock Overweight rating on July 09, 2019, issuing a price target of $165- $220. RBC Capital Mkts on their part issued Outperform rating on July 01, 2019.